IP Library › Granted Patent US 12,433,918
Granted Patent B2
US 12,433,918 · App. 18/141,056 · Granted Oct 7, 2025

Methods of treating joint disease, disorders, and conditions with tissue inhibitors of matrix metalloproteinase

Inventors: Jeffrey S. White (Birchrunville, PA); Robin R. Young (Beaverton, OR)
Assignee: Prime Merger Sub, LLC
A61K35/50A61K38/57A61L27/3604A61L27/54A61K9/0019A61K47/36A61L2300/434A61L2430/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,918
App. No.
18/141,056
Granted
Oct 7, 2025
Kind
B2
Abstract

Methods for treating joint diseases, disorders, and conditions, such as osteoarthritis, with a composition containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are provided. The composition can contain TIMPs as part of amniotic fluid, or the TIMPs can be isolated from another source or recombinantly produced. The methods are particularly useful for treating osteoarthritis associated with degradation of articular cartilage by proteases. Also provided are methods of lubricating a joint, such as an osteoarthritic joint.

Claims (20)

1. A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising injecting a composition comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) into a joint of the subject, thereby treating the joint disease, disorder, or condition, wherein the joint disease, disorder, or condition is associated with degradation of cartilage by proteases and the composition includes an amniotic fluid from which the TIMPS originate that is obtained from a pregnant female donor during a Caesarean section procedure, the amniotic fluid including a concentration of urea of no more than 160 mg/L, a concentration of uric acid of no more than 80 g/L and a concentration of creatinine of no more than 14 mg/L.

2. The method according to claim 1 , wherein the joint is selected from the group consisting of a synovial joint and a cartilaginous joint.

3. The method according to claim 1 , wherein the proteases comprise matrix metalloproteinases.

4. The method according to claim 1 , wherein the joint disease, disorder, or condition is selected from the group consisting of joint inflammation, osteoarthritis, rheumatoid arthritis, and chondromalacia patellae.

5. The method according to claim 1 , wherein particulate matter in an amniotic fluid is minimized.

6. The method according to claim 1 , including removing water from the amniotic fluid to enrich the amniotic fluid for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

7. The method according to claim 1 , wherein the joint disease, disorder, or condition is osteoarthritis of a synovial joint, wherein the osteoarthritis is associated with degradation of articular cartilage by proteases, and the composition is injected into the synovial joint.

8. The method according to claim 7 , wherein the proteases are matrix metalloproteinases.

9. The method according to claim 7 , wherein the synovial joint is a knee joint, wrist joint, shoulder joint, hip joint, elbow joint, or neck joint.

10. The method according to claim 1 , including removing substantially all endogenous components of the amniotic fluid with the exception of TIMPs to enrich the amniotic fluid for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

11. The method according to claim 1 , including determining that the amniotic fluid does not contain a therapeutically effective amount of the TIMPs and increasing the TIMPs concentration in the amniotic fluid whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

12. The method according to claim 1 , wherein the amniotic fluid is processed by removing water to enrich the amniotic fluid for endogenous TIMPs thereby providing a processed amniotic fluid having a TIMPs concentration selected from the group consisting of 10% w/v, 20% w/v, 30% w/v, 40% w/v, 50% w/v, 60% w/v, 70% w/v, 80% w/v, 90% w/v, 95% w/v and 99% w/v.

13. A method of lubricating an osteoarthritic joint in a subject in need thereof, wherein the osteoarthritis of the joint is associated with degradation of articular cartilage by proteases, the method comprising injecting into the joint a composition including a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases, thereby lubricating the osteoarthritic joint, wherein the composition includes an amniotic fluid from which the TIMPS originate that is obtained from a pregnant female donor during a Caesarean section procedure wherein the amniotic fluid includes a concentration of IL-6 of at least 329 ng/L, a concentration of IL-8 of at least 421 ng/L, a concentration of IL-1β of at least 3.9 ng/L and a concentration of TNF-α of at least 11.5 ng/L.

14. The method according to claim 13 , wherein the amniotic fluid is enriched for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs.

15. A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising injecting a composition including an enriched amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) into a joint of the subject, thereby treating the joint disease, disorder, or condition, wherein the amniotic fluid is enriched for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs, a concentration of α-globulins of at least 12% of a total protein concentration of the enriched amniotic fluid, a concentration of β-globulins of at least 16% of the total protein concentration and a concentration of γ-globulins of at least 12% of the total protein concentration, wherein the joint disease, disorder, or condition is associated with degradation of cartilage by proteases and the amniotic fluid is obtained from a pregnant female donor during a Caesarean section procedure.

16. The method according to claim 15 , wherein the joint is a synovial joint and the joint disease, disorder, or condition is osteoarthritis.

17. The method according to claim 15 , including adding recombinantly produced TIMPs to the amniotic fluid.

18. The method of claim 1 , wherein the amniotic fluid is enriched for endogenous protein.

19. The method of claim 13 , wherein the amniotic fluid is enriched for endogenous protein.

20. The method of claim 15 , wherein the amniotic fluid is enriched for endogenous protein.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2023
From: WHITE, JEFFREY S.
To: PRIME MERGER SUB, LLC
Reel/Frame 065501/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2023
From: YOUNG, ROBIN R.
To: PRIME MERGER SUB, LLC
Reel/Frame 064241/0802 →
Continuity (4)
Continuation 16746541 · Jan 17, 2020
Continuation 15086985 · Mar 31, 2016
Provisional Application 62140909 · Mar 31, 2015
Related Publication 20240058391A1 · Feb 22, 2024
References Cited (45)
US 5643752A · Hawkins · 1997 [cited by examiner]
Bunning et al., Eur. J. Biochem. 139: 75-80 (1984). [cited by examiner]
Murphy et al., Arthritis Res. 4(suppl 3): S39-S49 (2002). [cited by examiner]
Shimberg, J. Bone Joint Surg. 20(1): 167-177 (1938). [cited by examiner]
Bhattacharya, “Clinical Use of Amniotic Fluid in Osteoarthritis: A Source of Cell Therapy”, p. 395-403, Regenerative Medicine Using Pregnancy-Specific Biological Substances, Springer Verlag London, 2011. [cited by examiner]
Riley et al., J. Endocrinol. 162: 351-359 (1999). [cited by examiner]
Roopnarinesingh et al., J. Obstet. Gynaecol. Brit. Commonwealth 78: 29-33 (Jan. 1971). [cited by examiner]
Cox et al., Human Reproduction Update 3(5): 517-527 (1997). [cited by examiner]
Thomakos et al., Eur. J. Obstet. Gynecol. Reprod. Biol. 148: 147-151 (2010). [cited by examiner]
Srirangan et al., Ther. Adv. Musculoskel. Dis. 2(5): 247-256 (2010). [cited by examiner]
Perluigi et al., J. Prenatal Med. 3(3): 39-41 (2009). [cited by examiner]
Athayde et al. Matrix metalloproteinases-9 in preterm and term human parturition. J Matern. Fetal Med (1999) 8(5), 213-9. [cited by applicant]
Athyade et al. A role for matrix metalloproteinase-9 in spontaneous rupture of the fetal membranes. Am. J Obstet. Gynecol. (1998) 179(5), 1248-53. [cited by applicant]
Bole GG. Arthritis and Rheumatism 5(6):589-601 (1962). [cited by applicant]
Bryant-Greenwood et al. Control of peripartal collagenolysis in the human chorion-decidua. Am. J Obstet. Gynecol. (1995) 172 (1 Pt 1): 63. [cited by applicant]
Draper et al. Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Am. JObstet. Gynecol. (1995) 173(5) 1506. [cited by applicant]
Fortunato et al. Collagenolytic enzymes (gelatinases) and their inhibitors in human amniochorionic membrane. Am. JObstet. Gynecol. (1997) 177(4), 731-41. [cited by applicant]
Hampson et al. Amniotic membrane collagen content and type distribution in women with preterm premature rupture of the membranes in pregnancy. Br. J Obstet. Gynecol. (1997) 104(9), 1087. [cited by applicant]
Lei et al. 92 kDa gelatinase (matrix metalloproteinase-9) is induced in rat amnion immediately prior to parturition. Biol. Reprod (1995) 53(2): 339. [cited by applicant]
Maymon et al. A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. J Perinatal Medicine (2005) 29(4), 308-316. [cited by applicant]
McLaren et al. Increased concentration of pro-matrix metalloproteinase 9 in term fetal membranes overlying the cervix before labor: implications for membrane remodeling and rupture. [cited by applicant]
Menon et al. The role of matrix degrading enzymes and apoptosis in rupture of membranes. J Soc. Gynecol. Investig. (2004) 11(7), 427-37. [cited by applicant]
Moore et al. The physiology of fetal membrane rupture: insight gained from the determination of physical properties. Placenta (2006) 27(11-12) 1037-51. [cited by applicant]
Murphy et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008; 59(9): 1207-1213. [cited by applicant]
Murphy et al. One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage 2010; 18(11):1372-9. [cited by applicant]
Niknejad et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. (2008) 15, 88-99. [cited by applicant]
Trelford et al. The amnion in surgery, past and present. Am J Obstet Gynecol. (1979) 134(7): 833-45. [cited by applicant]
Vadillo-Ortega et al. 92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am. J Pathot (1995) 146(1), 148-56. [cited by applicant]
Vadillo-Ortego et al. Increased matrix metalloproteinase activity and reduced tissue inhibitor of metalloproteinases-1 levels in amniotic fluids from pregnancies complicated by premature rupture of membranes. Am. JObste… [cited by applicant]
Weiss et al. The matrix metalloproteinases (MMPs) in the decidua and fetal membranes. Frontiers in Bioscience (2007) 12, 649-59. [cited by applicant]
Wilson SE et al. IOVS 30(3):449-453 (1989). [cited by applicant]
Assali NA: Biology of Gestation, vol. 1, p. 2′76, New York, Academic Press, 1968. [cited by applicant]
Cenedella RJ. Biochimica et Biophysic Acta 793:448-454 (1984). [cited by applicant]
Fortunato et al. Presence of four tissue inhibitors of matrix metalloproteinases (TIMP-1, −2, −3, and −4) in human fetal membranes. Am. J Reprod ImmunoL (1998) 40(6), 395-400. [cited by applicant]
Treuhaft PS and DJ McCarty Arthritis & Rheumatism 14(4):475-484 (1971). [cited by applicant]
Cajori AF. J Biol Chem. 76:471-480 (1928). [cited by applicant]
Gordon et al. Metalloproteinase inhibitors as therapeutics. Clin. Exp. Rheumatol. (1993) Suppl. 8: S91-4. [cited by applicant]
Laurent UBG, RK Reed. Advance Drug Delivery Reviews 7:237-256 (1991). [cited by applicant]
Lu et al. Clinical significance of matrix metalloproteinase-9/tissue inhibitors of matrix metalloproteinase-1 imbalance in maternal serum, amniotic fluid, umbilical cord serum in patients with premature rupture of the m… [cited by applicant]
Park et al. Role of cytokines in preterm labor and birth. Minerva Ginecol. (2005) 57(4), 349-66. [cited by applicant]
Pasquier et al. Fetal membranes: embryological development, structure and the physiopathology of the preterm premature rupture of membranes. J Gynecol. Obstet. Biol. Reprod (Paris) (2008) 37(6), 579-88. [cited by applicant]
Schmidt TA et al. JANIA Ophthalmol 131(6):766-776 (2013). [cited by applicant]
Wang et al. Role of matrix metalloproteinases-2,9 and their inhibitors in premature rupture of membranes. Zhonghua Fu Chan Ke Za Zhi (2005) 40(1) 29-33. [cited by applicant]
Engstrom-Laurent A and TC Laurent. Clinical Impact of Bone and Connective Tissue Markers p. 237 Academic Press 1989 (AF values are for 16 weeks and 39 weeks gestation, respectively). [cited by applicant]
Osteoarthritis: Diagnosis and Medical/Surgical Management (Moskowitz ed.), p. 207 Lippincott Williams & Wilkins (2007). [cited by applicant]